BPC-157 (Body Protection Compound-157)
Identification
| Property |
Value |
| CAS Number |
137525-51-0 |
| Sequence |
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular Formula |
C₆₂H₉₈N₁₆O₂₂ |
| Molecular Weight |
~1,419.5 Da |
| Amino Acid Count |
15 |
| Appearance |
White to off-white lyophilized powder |
| Solubility |
Soluble in water, saline, or aqueous buffers |
Research Applications
BPC-157 is a synthetic peptide derived from a protective protein found in human gastric juice. The peptide is the subject of extensive preclinical investigation across multiple therapeutic areas:
Primary Research Domains
| Area |
Key Findings |
| Tendon & Ligament Healing |
Accelerates fibroblast proliferation and collagen organization at injury sites; improves biomechanical recovery in animal tendon transection models |
| Angiogenesis |
Promotes VEGF receptor expression and new capillary formation; facilitates granulation tissue development |
| Gastrointestinal Protection |
Counteracts NSAID-induced lesions in gastric and intestinal mucosa; maintains endothelial integrity in experimental colitis models |
| CNS Injury & Neuroprotection |
Attenuates traumatic brain injury outcomes; promotes neuronal survival and axonal regeneration in spinal cord injury models |
| Bone Healing |
Enhances osteoblast activity and accelerates callus formation in fracture models |
Mechanisms of Action
| Mechanism |
Description |
| VEGF Upregulation |
Increases vascular endothelial growth factor expression, driving angiogenesis and perfusion at injury sites |
| Growth Hormone Receptor Modulation |
Modulates GH receptor expression in fibroblasts, enhancing proliferative response during repair phases |
| Nitric Oxide (NO) System |
Preserves endothelial NO synthase activity; maintains vasodilatory and cytoprotective signaling |
| FAK-Paxillin Pathway |
Activates focal adhesion kinase (FAK) and paxillin signaling, promoting fibroblast migration and focal adhesion turnover essential for wound closure |
| Dopaminergic & Serotonergic Systems |
Modulates central neurotransmitter systems, contributing to observed neuroprotective effects |
Quality Specifications
| Parameter |
Specification |
Method |
| Purity (HPLC) |
≥99.0% |
Reverse-phase HPLC, C18 column, 214 nm detection |
| Mass Identity |
Molecular weight ±1.0 Da |
ESI-MS (Electrospray Ionization Mass Spectrometry) |
| Water Content |
≤3.0% |
Karl Fischer titration |
| Peptide Content |
≥80.0% |
Amino acid analysis or nitrogen determination |
| Acetate Content |
≤15.0% (TFA salt); ≤1.0% (acetate salt) |
Ion chromatography |
| Residual Solvents |
≤ ICH Q3C limits |
Headspace GC |
| Endotoxin |
≤1.0 EU/mg |
LAL kinetic chromogenic method |
| pH |
4.0–7.0 (1 mg/mL in water) |
Potentiometric |
| Appearance of Solution |
Clear, colorless |
Visual inspection |
Available Configurations
| Format |
Catalog Size |
Vials per Kit |
Notes |
| Standard Research Kit |
5 mg × 10 vials |
10 |
Recommended for most laboratory protocols |
| Extended Research Kit |
10 mg × 10 vials |
10 |
For higher-throughput experimental designs |
| Bulk Research Packaging |
Custom |
Custom |
OEM and contract research quantities available |
Storage & Stability
| Condition |
Requirement |
| Short-term Storage |
2–8°C, lyophilized form |
| Long-term Storage |
−20°C to −80°C, desiccated environment |
| Light Sensitivity |
Protect from direct light; store in amber vials or opaque containers |
| Reconstituted Solution |
Use within 24 hours when stored at 2–8°C; aliquot and freeze at −20°C for extended use |
| Shipping |
Ambient temperature acceptable for ≤14 days during transit |
Documentation & Quality Assurance
- Certificate of Analysis (COA): Provided with every batch; includes HPLC chromatogram, MS spectrum, and quantitative purity data. See our COA & Purity Analysis Guide.
- Material Safety Data Sheet (MSDS): Available for download with each shipment.
- Batch Traceability: Every vial carries a unique serial number linked to the manufacturing batch record.
Special Notes
- FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, diagnostic procedures, or therapeutic applications.
- Custom synthesis available upon request, including specific salt forms (acetate, hydrochloride) and net peptide content adjustments.
- OEM and private-label configurations: contact us for project scoping and minimum order quantities.
- All products manufactured under ISO 9001:2015 quality management systems with full batch record documentation.
Key Research References
| Reference |
PMID |
Key Finding |
| Sikiric P et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des. 2011;17(16):1612–1632. |
21548867 |
BPC-157 promotes endothelial integrity and angiogenesis via VEGFR2 activation; counteracts NSAID-induced GI lesions |
| Chang CH et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774–780. |
21030672 |
BPC-157 accelerates fibroblast proliferation and migration; enhances collagen organization at tendon injury sites |
| Vukojevic J et al. "Pentadecapeptide BPC 157 and the central nervous system." Neural Regen Res. 2022;17(3):482–487. |
34380875 |
BPC-157 attenuates CNS injury outcomes; promotes neuronal survival and axonal regeneration after traumatic brain and spinal cord injury |
Stability & Storage
| Condition |
Degradation Profile |
| Gastric Juice (pH 1–3) |
Stable; the peptide is originally derived from gastric juice and retains full activity in acidic environments |
| Neutral pH (6.5–7.5) |
Stable; optimal stability range for reconstituted solutions |
| Alkaline pH (>8.0) |
Degrades rapidly; avoid alkaline buffers during reconstitution and storage |
| Temperature |
Lyophilized: stable 24 months at 2–8°C, 36 months at −20°C. Reconstituted: 24 h at 4°C; freeze at −20°C for ≤30 days |
| Light Exposure |
Protect from light; store in amber vials or opaque containers |
| Freeze-Thaw |
Avoid repeated cycles; aliquot into single-use portions after initial reconstitution |
Frequently Asked Questions
Q: What purity specifications apply to BPC-157?
≥99.0% by HPLC at 214 nm with ESI-MS mass identity confirmation (±1.0 Da). Each batch is tested for peptide content (≥80.0%), water content (≤3.0%), and TFA/acetate. Full batch-specific COA with HPLC chromatogram and MS spectrum included with every order.
Q: How should BPC-157 be stored after reconstitution?
Reconstituted BPC-157 is stable for 24 hours at 2–8°C. For longer storage, aliquot into single-use sterile vials and freeze at −20°C. Avoid alkaline buffers (pH > 8) — the peptide degrades under alkaline conditions. Do not subject to repeated freeze-thaw cycles; aliquot upon initial reconstitution to maintain integrity.
Source & Purchase
For researchers requiring BPC 157 with full analytical documentation including HPLC and LC-MS traces, visit the PeptideSourceHub product page for bulk pricing and specifications.
Purchase BPC 157 with COA →
| Product |
Link |
| TB-500 (Thymosin Beta-4 Fragment) |
tb-500.md — Actin-binding domain fragment |
| Thymosin Beta-4 (Full Length) |
thymosin-beta-4.md — Full 43-aa tissue regeneration peptide |
| ARA-290 |
ara-290.md — Innate Repair Receptor agonist |
| GHK-Cu |
ghk-cu.md — Copper tripeptide for wound healing & collagen |